https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8027 Sat 24 Mar 2018 08:36:47 AEDT ]]> Assuring high quality treatment delivery in clinical trials: results from the Trans-Tasman Radiation Oncology Group (TROG) study 03.04 "RADAR" set-up accuracy study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7330 Sat 24 Mar 2018 08:35:12 AEDT ]]> Quality improvements in prostate radiotherapy: outcomes and impact of comprehensive quality assurance during the TROG 03.04 'RADAR' trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18210 Sat 24 Mar 2018 08:04:37 AEDT ]]> A randomised trial investigating the effect on biochemical (PSA) control and survival of different durations of adjuvant androgen deprivation in association with definitive radiation treatment for localised carcinoma of the prostate https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33247 7 cutpoint identified in 2014 for the BP and STI endpoints. A tertiary objective of the trial is to determine whether intercurrent medical conditions will impact independently on delayed radiotherapy morbidity and other treatment related morbidity.]]> Mon 23 Sep 2019 13:37:53 AEST ]]> Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34907 interaction = -1.3 s, 95% confidence interval [CI] -2.6 to 0.0), whole-body lean mass (ßinteraction = 1194 g, 95% CI 234 to 2153) and ASM mass (ßinteraction = 562 g, 95% CI 49 to 1075), and approached significance for fat mass (ßinteraction = -1107 g, 95% CI -2346 to 132), with greater benefits for men previously on long-term ADT. At 6 months, the intervention effects on chair rise time -1.5 s (95% CI -2.5 to -0.5), whole-body lean mass 824 g (95% CI 8 to 1640), ASM mass 709 g (95% CI 260 to 1158), and fat mass -1377 g (95% CI -2156 to -598) were significant for men previously on long-term ADT, but not for men on short-term ADT. At 12 months, the intervention effects for men on long-term ADT remained significant for the chair rise, with improved performance (-2.0 s, 95% CI -3.0 to -1.0) and increased ASM (537 g, 95% CI 153 to 921). Time on ADT did not moderate the exercise effects on muscle strength, nor did time since ADT cessation moderate any intervention effects. Similarly, testosterone and baseline values of the outcome had negligible moderator effects. Conclusions: Men with PCa previously treated long-term with ADT respond more favourably to exercise in terms of lower body muscle performance and body composition (lean and fat mass, and ASM) than those with short-term ADT exposure. As a result, men who were formerly on long-term androgen suppression regimens should be especially prescribed exercise medicine interventions to alleviate residual treatment-related adverse effects.]]> Fri 01 Apr 2022 09:25:19 AEDT ]]>